Abstract: The present invention relates to an improved process for the preparation of 4-amino-N-tert-butyl-4,5-dihydro-3-isopropyl-5-oxo-1H-1,2,4-triazole-1-carboxamide (Amicarbazone). The present invention more particularly relates to an improved process for the preparation of 4-amino-N-tert-butyl-4,5-dihydro-3-isopropyl-5-oxo-1H-1,2,4-triazole-1-carboxamide (Amicarbazone) by coupling of 4-Amino-2,4-dihydro-5-(1-methylethyl)-3H-1,2,4-triazol-3-one (TAZ) and poor quality tert-Butyl isocyanate (TBIC) with purity less than or equal to 98%, preferably less than or equal to 85%.

Abstract: A system and method for facilitating and automating regulatory compliance requirements for business entities across various industries. The system includes a secure cloud assembly for the business entity that contains confidential and private information belonging to the entity. A compliance agent in the assembly has external communications with an external compliance database and an external compliance processing server. One or more user workstations has access to confidential and private information contained within the secure cloud assembly. The workstation also has access to the compliance processing server and a communication application for review and meeting compliance requirements. The system automatically monitors and alerts a user to a compliance agenda and requirements, we well as, generates meeting minutes and compliance reports. The method utilizes the described system.

Abstract: The present invention relates to an improved process for the preparation of 4-amino-N-tert-butyl-4,5-dihydro-3-isopropyl-5-oxo-1H-1,2,4-triazole-1-carboxamide (Amicarbazone). The present invention more particularly relates to an improved process for the preparation of 4-amino-N-tert-butyl-4,5-dihydro-3-isopropyl-5-oxo-1H-1,2,4-triazole-1-carboxamide (Amicarbazone) by coupling of 4-Amino-2,4-dihydro-5-(1-methylethyl)-3H-1,2,4-triazol-3-one (TAZ) and poor quality tert-Butyl isocyanate (TBIC) with purity less than or equal to 98%, preferably less than or equal to 85%.

Abstract: The invention provides novel immunological adjuvants and methods for identification of such adjuvants. The invention further provides methods and compositions for eliciting an immune response to an immunogen using the novel adjuvants. The adjuvants can be employed with any suitable immunogen, including proteins, peptides, lipids, and carbohydrates. The immunogen can be derived from a virus, a cancer, or a diseased cell. The elicited immune response can be cellular, humoral, or both.

Abstract: The present invention relates to prophylactic and therapeutic methods of immunization against neoplastic and infectious diseases. The invention provides a method for identification of novel immunogens and compositions of such immunogens that are useful for eliciting immune responses against antigens associated with neoplastic or infectious diseases.

Abstract: The invention provides novel immunological adjuvants and methods for identification of such adjuvants. The invention further provides methods and compositions for eliciting an immune response to an immunogen using the novel adjuvants. The adjuvants can be employed with any suitable immunogen, including proteins, peptides, lipids, and carbohydrates. The immunogen can be derived from a virus, a cancer, or a diseased cell. The elicited immune response can be cellular, humoral, or both.

Abstract: Described herein are systems and methods for transforming a speech input into machine-interpretable structured data. In some embodiments, a system may include an automated speech recognition (ASR) engine configured to receive a live speech input and to continuously generate a text of the live speech input, a natural language processing (NLP) engine configured to transform the text into machine-interpretable structured data, and a user interface device configured to display the live speech input and a corresponding portion of the structured data in a predetermined order with respect to the structured data. In some embodiments, the method may include the steps of receiving a speech input with a speech capture component of a user interface device, generating a text from the speech input, identifying textual cues in the text, modifying the text based on the textual cues, and transforming the modified text into machine-interpretable structured data.

Abstract: The present invention relates to prophylactic and therapeutic methods of immunization against neoplastic and infectious diseases. The invention provides a method for identification of novel immunogens and compositions of such immunogens that are useful for eliciting immune responses against antigens associated with neoplastic or infectious diseases.

Abstract: The present invention relates to prophylactic and therapeutic methods of immunization against neoplastic and infectious diseases. The invention provides a method for identification of novel immunogens and compositions of such immunogens that are useful for eliciting immune responses against antigens associated with neoplastic or infectious diseases.

Abstract: A method and apparatus for agent-less auditing of a server, wherein the apparatus processes data for auditing a server. One or more portions of audit information (e.g., transaction log, trace log, or both) are coupled from a target server to an information server. The one or more portions of the audit information are processed at the information server to create audit data. The audit data is stored in an audit data repository.

Abstract: The invention is directed to 1-nitroacridine derivative(s)/tumor inhibitor(s) compositions as well as methods for using said compositions for inhibiting or preventing tumor growth, particularly, prostate cancer cell growth and metastases.

Abstract: The present invention relates to prophylactic and therapeutic methods of immunization against neoplastic and infectious diseases. The invention provides a method for identification of novel immunogens and compositions of such immunogens that are useful for eliciting immune responses against antigens associated with neoplastic or infectious diseases.

Abstract: The invention is directed to novel 9-hydroxyalkylamino-, 9-alkoxyalkylamino-1-nitroacridine derivatives. Methods of preparation, pharmaceutical compositions comprising said derivatives and their medical uses are also encompassed by this invention.

Abstract: The invention is directed to novel 9-hydroxyalkylamino-, 9-alkoxyalkylamino-1- nitroacridine derivatives. Methods of preparation, pharmaceutical compositions comprising said derivatives and their medical uses are also encompassed by this invention.

Abstract: The invention is directed to 1-nitroacridine derivative(s)/tumor inhibitor(s) compositions as well as methods for using said compositions for inhibiting or preventing tumor growth, particularly, prostate cancer cell growth and metastases.